Patients with NMO had significantly lower levels of anti-PAD2 antibodies [0.21 (0.15–0.46) anti-PAD2 AU] than patients with MS, PTLD, or healthy controls (padj < 0.0001 for all; Figure 2). Here, PADI2 is linked to myeloid sarcoma.